BioWorld Asia

March 29, 2006

NicOx Expands Merck Deal For Up To $350M

A research collaboration that started in August 2003 came full circle when French company NicOx SA granted Merck & Co. Inc. exclusive worldwide development and marketing rights to nitric oxide-donating drugs for hypertension. (BioWorld International) Read More

Pharming Acquiring DNAge: Milestones, EUR15M In Shares

Mutant Yeast Show Details Of Telomere Maintenance

Europe’s Biotech Industry Energized By EU Summit

PanGenetics Brings In EUR13M For Antibody Development

Pfizer Licenses, Invests In Noxxon’s Spiegelmer Drugs

Biotech Pipelines Sitting Unexploited’ In Australia

Speedel Raises CHF79.7M In Sale Of Treasury Shares

BioSystems Licenses Biomarker Technology From Northeastern

Diagnostics Seen As Hope For Future Of Health Care

Biofusion, NPI Set UP £10M Fund To Fuel Biotech Firms

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

In 2025, science’s biggest story was political

BioWorld

In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...

Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis

BioWorld Science

Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...